{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:55:41Z","timestamp":1776318941134,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data on secukinumab in Chinese psoriatic arthritis (PsA) patients remain limited, particularly regarding short-term cutaneous response, dermatology-specific quality of life, and predictors of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was performed using 446 PsA patients diagnosed based on the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria and treated with secukinumab for &amp;gt;12\u202fweeks. Skin severity and quality of life were assessed using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Investigator\u2019s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI) at baseline and after treatment. Treatment-related adverse events (TRAEs) were graded according to CTCAE v5.0. A predictive nomogram was constructed using stepwise multivariate regression and validated using the receiver operating characteristic (ROC) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort of 446 PsA patients (mean age 47.7\u202fyears; 65.2% men) exhibited significant improvements across all domains. Post-treatment PASI decreased from 14.2\u202f\u00b1\u202f14.4 to 3.98\u202f\u00b1\u202f8.84 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), and DLQI improved from 11.9\u202f\u00b1\u202f7.44 to 4.41\u202f\u00b1\u202f5.63 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). The correlation between PASI and DLQI significantly strengthened post-treatment (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      increased from 0.34 to 0.52, \u0394\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f+0.18;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), accompanied by a steeper regression slope (0.3479 vs. 0.2229). Post-treatment objective-subjective outcome intercorrelations were robust (IGA-PASI\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.86, PASI-DLQI\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.62, all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). A predictive nomogram incorporating five baseline variables \u2014 PASI score, disease duration, patient age, baseline BSA, and body mass index (BMI) \u2014 was developed and internally validated (AUC\u202f=\u202f0.764, 95% CI: 0.712\u20130.816) for predicting cutaneous treatment response. Higher baseline PASI scores, longer disease duration, greater baseline BSA, older age, and lower BMI were associated with higher predicted probability of achieving treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of Chinese PsA patients, secukinumab demonstrates robust clinical short-term efficacy in skin severity and dermatology-specific quality of life, with a favorable short-term safety profile. The predictive nomogram may assist in estimating short-term cutaneous response, although external validation is required. However, these findings are specific to PsA patients and should not be extrapolated to psoriasis populations without musculoskeletal involvement, given the additional disease-burden dimensions in PsA that influence quality-of-life outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1773701","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:38Z","timestamp":1776317138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world skin and dermatology-specific quality-of-life outcomes and a nomogram to predict skin response to secukinumab in Chinese psoriatic arthritis patients: a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lihua","family":"Zhang","sequence":"first","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangxi University of Traditional Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Gong","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"Candidate Branch of National Clinical Research Center for Skin Diseases","place":["Nanchang, China"]},{"name":"National Clinical Research Center for Skin and Immune Disease","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"Hu","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Jiangxi Province","place":["Nanchang, China"]},{"name":"The Affiliated Dermatology Hospital of Nanchang University","place":["Nanchang, China"]},{"name":"Jiangxi University of Traditional Chinese Medicine","place":["Nanchang, China"]},{"name":"Candidate Branch of National Clinical Research Center for Skin Diseases","place":["Nanchang, China"]},{"name":"National Clinical Research Center for Skin and Immune Disease","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/acr.23896","article-title":"Patients' perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies","volume":"72","author":"Sumpton","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The Il-23-Il-17 immune Axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/09546634.2018.1527994","article-title":"Treatment of psoriatic arthritis with secukinumab: a case series","volume":"29","author":"Nicola","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17a monoclonal antibody, in patients with psoriatic arthritis (future 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (sculpture extension study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","article-title":"Real-world evidence of Secukinumab in psoriasis treatment - a Meta-analysis of 43 studies","volume":"34","author":"Augustin","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1426127","DOI":"10.3389\/fimmu.2024.1426127","article-title":"Early detection of psoriatic arthritis in patients with psoriasis: construction of a multifactorial prediction model","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1764025","DOI":"10.3389\/fmed.2026.1764025","article-title":"Machine learning-based prediction of Pasi100 response to Secukinumab in patients with psoriasis: a real-world study with Shap interpretability analysis","volume":"13","author":"Hu","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1643591","DOI":"10.3389\/fimmu.2025.1643591","article-title":"Development and validation of a novel nomogram for predicting outcomes in advanced lung Cancer patients treated beyond progression with immune checkpoint inhibitors","volume":"16","author":"Luo","year":"2025","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 future 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (Dlqi): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e002939","DOI":"10.1136\/rmdopen-2022-002939","article-title":"Secukinumab improves physical function and quality of life and inhibits structural damage in patients with Psa with sustained remission or low disease activity: results from the 2-year phase 3 future 5 study","volume":"9","author":"Coates","year":"2023","journal-title":"RMD Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 future 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/CM9.0000000000002860","article-title":"Efficacy of Interleukin-17 inhibitors on radiographic progression in psoriatic arthritis: a systematic review and Meta-analysis","volume":"137","author":"Jiang","year":"2024","journal-title":"Chin Med J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (Immvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (Uncover-2 and Uncover-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/09546634.2020.1839009","article-title":"Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey","volume":"33","author":"Yildirim","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jdv.12850","article-title":"Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis","volume":"30","author":"Phan","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2633794","DOI":"10.1080\/09546634.2026.2633794","article-title":"Clinical characteristics, effectiveness, safety, and predictors of Pasi75\/90 responses to Il-17 biologics in psoriasis involving special sites: a large real-world cohort study revealing treatment response heterogeneity","volume":"37","author":"Hu","year":"2026","journal-title":"J Dermatolog Treat"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/S0140-6736(20)31024-2","article-title":"Obesity could shift severe Covid-19 disease to younger ages","volume":"395","author":"Kass","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1773701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:39Z","timestamp":1776317139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1773701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1773701"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1773701","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1773701"}}